Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx? for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy.

Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx? for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Oct; 26(10):3232-3239.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Chemotherapy, Adjuvant
Female
Follow-Up Studies
Gene Expression Profiling
Humans
Medical Overuse
Middle Aged
Neoadjuvant Therapy
Prognosis
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Retrospective Studies